PL447563A1 - Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji - Google Patents

Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji

Info

Publication number
PL447563A1
PL447563A1 PL447563A PL44756324A PL447563A1 PL 447563 A1 PL447563 A1 PL 447563A1 PL 447563 A PL447563 A PL 447563A PL 44756324 A PL44756324 A PL 44756324A PL 447563 A1 PL447563 A1 PL 447563A1
Authority
PL
Poland
Prior art keywords
strain
lacticaseibacillus
strains
lpc100
paracasei
Prior art date
Application number
PL447563A
Other languages
English (en)
Inventor
Bożena Cukrowska
Joanna Leszczyńska
Tamara Aleksandrzak-Piekarczyk
Agnieszka SZCZEPANKOWSKA
Original Assignee
Nordic Biotic Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Biotic Spółka Z Ograniczoną Odpowiedzialnością filed Critical Nordic Biotic Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL447563A priority Critical patent/PL447563A1/pl
Publication of PL447563A1 publication Critical patent/PL447563A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Przedmiotami wynalazku są szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji. Bardziej szczegółowo rozwiązanie dotyczy wysoce aktywnych szczepów oraz kompozycji wykazującej synergistyczny efekt w procesie hydrolizy immunoreaktywnych peptydów gliadyny.
PL447563A 2024-01-22 2024-01-22 Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji PL447563A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL447563A PL447563A1 (pl) 2024-01-22 2024-01-22 Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447563A PL447563A1 (pl) 2024-01-22 2024-01-22 Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji

Publications (1)

Publication Number Publication Date
PL447563A1 true PL447563A1 (pl) 2025-07-28

Family

ID=96498406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447563A PL447563A1 (pl) 2024-01-22 2024-01-22 Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji

Country Status (1)

Country Link
PL (1) PL447563A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170039A1 (en) * 2005-03-16 2011-04-29 Actial Farmac Utica Lda Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
WO2013192163A1 (en) * 2012-06-18 2013-12-27 H.J. Heinz Company Gluten-related disorders
WO2015177366A1 (en) * 2014-05-23 2015-11-26 Consejo Superior De Investigaciones Científicas (Csic) New strain of lactobacillus casei with ability to degrade the immunotoxic peptide from gluten
US20170145379A1 (en) * 2010-03-12 2017-05-25 Compagnie Gervais Danone Lactic Acid Bacteria for Coeliac Disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170039A1 (en) * 2005-03-16 2011-04-29 Actial Farmac Utica Lda Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
US20170145379A1 (en) * 2010-03-12 2017-05-25 Compagnie Gervais Danone Lactic Acid Bacteria for Coeliac Disease
WO2013192163A1 (en) * 2012-06-18 2013-12-27 H.J. Heinz Company Gluten-related disorders
WO2015177366A1 (en) * 2014-05-23 2015-11-26 Consejo Superior De Investigaciones Científicas (Csic) New strain of lactobacillus casei with ability to degrade the immunotoxic peptide from gluten

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALTOMARE, A.; DI ROSA, C.; IMPERIA, E.; EMERENZIANI, S.; CICALA, M.; GUARINO, M.P.L.,: "Nutrients, 2021, 13, 1506", DIARRHEA PREDOMINANT-IRRITABLE BOWEL SYNDROME (IBS-D): EFFECTS OF DIFFERENT NUTRITIONAL PATTERNS ON INTESTINAL DYSBIOSIS AND SYMPTOMS, DOI: https://doi.org/10.3390/nu13051506 *
GROŃSKA D, DRZEWOWSKA K.,: "Medycyna Ogólna i Nauki o Zdrowiu; 2022, 28(4): 295–300.", POSTCOVIDOWY ZESPÓŁ JELITA NADWRAŻLIWEGO – ZNACZENIE DIETOTERAPII ORAZ PROBIOTYKOTERAPII, DOI: 10.26444/monz/155260 *
HABIBI-NAJAFI MB, LEE BH: "J Dairy Sci., 1994; 77(2):385-92", PROLINE-SPECIFIC PEPTIDASES OF LACTOBACILLUS CASEI SUBSPECIES., DOI: 10.3168/jds.S0022-0302(94)76964-2. PMID: 7910174 *
SKRZYDŁO-RADOMAŃSKA B. I IN.,: "Nutrients, 2021, 13, 756.", THE EFFECTIVENESS AND SAFETY OF MULTI-STRAIN PROBIOTIC PREPARATION IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED STUDY., DOI: https://doi.org/10.3390/nu13030756 *
ZOLNIKOVA, O. I IN.,: "Microorganisms, 2023, 11, 2848.", THE CONTRIBUTION OF THE INTESTINAL MICROBIOTA TO THE CELIAC DISEASE PATHOGENESIS ALONG WITH THE EFFECTIVENESS OF PROBIOTIC THERAPY, DOI: https://doi.org/10.3390/microorganisms11122848 *

Similar Documents

Publication Publication Date Title
Crespo Erchiga et al. Malassezia globosa as the causative agent of pityriasis versicolor
Erchiga et al. Malassezia globosa as the causative agent of pityriasis versicolor
SE9102238D0 (sv) Tarmkoloniserande laktobaciller
UA42092C2 (uk) Штам молочнокислих бактерій bifidobacterium breve, штам молочнокислих бактерій bifidobacterium infantis, штам молочнокислих бактерій bifidobacterium longum для покращення кишкової флори, спосіб покращення кишкової флори
WO2009142472A3 (es) Bifidobacteria productora de ácido fólico, composición alimenticia y uso de la bifidobacteria
SU1720493A3 (ru) Способ получени штамма SтRертососсUS SaNGUIS, способного секретировать @ -1,3-глюкан-3-глюканогидролазу
MX2023009930A (es) Pre-acondicionamiento de l. reuteri con gos y gos en formulacion final.
Barata et al. Purification and characterization of an extracellular trypsin-like protease of Fusarium oxysporum var. lini
PL447563A1 (pl) Szczep Lacticaseibacillus (L.) casei LC130, szczep Lacticaseibacillus (L.) paracasei LPC100, szczep Streptococcus (S.) salivarius ssp. thermophilus ST250, kompozycja obniżająca immunoreaktywność peptydów gliadyny oraz zastosowanie szczepów do wytwarzania kompozycji
CA2299627A1 (en) Novel lactic acid bacteria
Van Strijp et al. Bacterial colonization and degradation of demineralized dentin matrix in situ
AR129336A1 (es) Bacteria ácido láctica resistente a fagos
EP0524732B1 (en) Composition containing lactic acid bacteria for preventing dental caries
KR102262644B1 (ko) 피부 상재균총 조절효과를 갖는 하이브리드 박테리얼 셀룰로오스 마스크 시트 및 이의 제조방법
Fletcher et al. Analysis of the effect of changing environmental conditions on the expression patterns of exported surface-associated proteins of the oral pathogen Actinobacillus actinomycetemcomitans
ES475972A1 (es) Produccion de liofilizado de enzimas descompuetas.
WO2023281415A3 (en) Bacteria strains for topical skin care
CN118902973A (zh) 一种抗衰发酵产物与多肽的组合物及其在制备护肤品中的应用
Samdani et al. The proteolytic activity of strains of T. mentagrophytes and T. rubrum isolated from tinea pedis and tinea unguium infections
PL392425A1 (pl) Sposób wytwarzania fermentowanych, prozdrowotnych napojów owocowych
YU23490A (sh) Farmaceutski preparat za lečenje tonzilitisa
CN204653644U (zh) 一种改善口腔健康的脂肪酶口香糖片
MX2023010518A (es) Preacondicionamiento de cepas de lactobacillus con gos y gos en la formulacion final.
Rogers Why be down in the mouth? Three decades of research in oral microbiology
Yeasmin et al. Isolation of biotechnologically important enzyme producing Rhizobacteria from seasonal flower beds